Long-term efficacy and safety of ixekizumab - interview with Andrew Blauvelt

Dr. Andrew Blauvelt is the first author of a recent paper which analyzes long-term efficacy and safety of ixekizumab in psoriasis. Dr. Blauvelt tell us what was the message of this study for the dermatologist society and why it is important for their patients. Video: https://congressreport.eu/scientific-contents/standalonecontent:long-term-efficacy-and-safety-ixekizumab The full article: Long-term efficacy and safety of ixekizumab: A 5-year analysis of the UNCOVER-3 randomized controlled trial https://www.jaad.org/article/S0190-9622(20)33053-X/fulltext